A5000966632- Antifungal resistance and susceptibility
- Parasitic Diseases Research and Treatment
- Antibiotics Pharmacokinetics and Efficacy
- Mycobacterium research and diagnosis
- SARS-CoV-2 and COVID-19 Research
- Phagocytosis and Immune Regulation
- Pharmaceutical studies and practices
- Tuberculosis Research and Epidemiology
- Hormonal Regulation and Hypertension
- Receptor Mechanisms and Signaling
- Sepsis Diagnosis and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Cystic Fibrosis Research Advances
- COVID-19 Clinical Research Studies
- Pharmaceutical and Antibiotic Environmental Impacts
- Infectious Diseases and Mycology
- Herbal Medicine Research Studies
- Gene expression and cancer classification
- Molecular Biology Techniques and Applications
- Fungal Infections and Studies
- Advanced Drug Delivery Systems
- Antimicrobial Resistance in Staphylococcus
- Autoimmune Bullous Skin Diseases
- Poisoning and overdose treatments
- Antibiotic Resistance in Bacteria
National Institutes of Health Clinical Center
2016-2024
National Institutes of Health
2020
Cubist Pharmaceuticals (United States)
2018
Resurrection Health Care
2012
University of the Sciences
2012
Abstract Background Coronavirus disease 2019 (COVID-19) requiring hospitalization is characterized by robust antibody production, dysregulated immune response, and immunothrombosis. Fostamatinib a novel spleen tyrosine kinase inhibitor that we hypothesize will ameliorate Fc activation attenuate harmful effects of the anti-COVID-19 response. Methods We conducted double-blind, randomized, placebo-controlled trial in hospitalized adults oxygen with COVID-19 where patients receiving standard...
Abstract Nontuberculous mycobacteria (NTM) can cause a variety of infections, including serious pulmonary disease. Treatment encompasses polypharmacy, with targeted regimen 2–5 active medications, depending on site infection, species, and clinical characteristics. Medications may include oral, intravenous, inhalational routes. Medication acquisition be challenging for numerous reasons, investigational status, limited distribution models, insurance prior authorization. Additionally,...
Candida albicans causes debilitating, often azole-resistant, infections in patients with chronic mucocutaneous candidiasis (CMC). Amphotericin B (AMB) resistance is rare, but AMB use limited by parenteral administration and nephrotoxicity.
Current oral therapeutic options for chronic mucocutaneous candidiasis (CMC) are often associated with resistance and toxicity. Amphotericin B (AMB) has broad fungicidal activity markedly resists emergence of but requires parenteral administration monitoring significant nephrotoxicity, which worsens treatment. Encochleated amphotericin (CAMB) is a novel formulation AMB. In animal models, CAMB demonstrates antifungal similar efficacy as intraperitoneal AMB deoxycholate, without the This...
A national survey was conducted to evaluate the use of continuous and extended infusions for administering β-lactams vancomycin.The sent a random sample 1000 acute care hospital pharmacists in United States antibiotics. In addition, same members Society Infectious Diseases Pharmacists (SIDP) assess adoption these infusion strategies.In random-sample survey, 29 (11.2%) 15 (5.8%) hospitals reported using infusions, respectively. Common rationales adopting were greater efficacy, equal or less...
Paecilomyces variotii is an opportunistic mold that causes pulmonary infections in immunosuppressed humans are often treated with triazole therapy. Lupus nephritis a major cause of progressive kidney disease patients systemic lupus erythematosus, requiring cyclophosphamide-based therapies. Triazole-cyclophosphamide co-administration challenging as triazoles increase cyclophosphamide concentrations, which can worsen toxicity. We describe herein patient pneumonia and concomitant who was...
Abstract Background Candida albicans causes debilitating mucosal infections in patients with inherited susceptibility to chronic mucocutaneous candidiasis (CMC), often requiring long-term azole-based treatment. Due increasing azole resistance, alternative treatments are desirable. Acquired resistance amphotericin B (AMB) is rare but AMB use limited by parenteral administration and nephrotoxicity. Cochleated (CAMB) a new oral formulation of thus an attractive option for oropharyngeal (OPC),...